YOKOGAWA-ELECTRIC
Yokogawa Electric Corporation (TOKYO: 6841) announces the release of artificial intelligence (AI)-enabled versions of the GX series panel-mount type paperless recorders, GP series portable paperless recorders, and GA10 data logging software, which are components of the highly operable and expandable SMARTDAC+TM data acquisition and control system. This new AI functionality includes the future pen, a function developed by Yokogawa that enables the drawing of predicted waveforms. Yokogawa is also releasing a new CPU module for the e-RT3TM Plus edge computing platform that is environmentally robust and PythonTM*1 compatible. The GX/GP and e-RT3 Plus release is set for April 8, and the GA10 software will be released on May 13. The SMARTDAC+ system is a product in the OpreXTM Data Acquisition family, and the e-RT3 Plus is part of the OpreX Control Devices family.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200407005269/en/
The introduction of AI functions such as the future pen, a first for industrial recorders*2 , will help users identify and correct problems before they have a chance to cause disruptions in production operations.
Background
There is a rising interest in the manufacturing sector in the use of AI to prevent equipment malfunctions and maximize productivity. At the same time, AI technologies have a steep learning curve, and the introduction of existing AI-enabled products and the analysis of their data is typically beyond the expertise of novices to this field.
Recorders are used in manufacturing and R&D to acquire, display, and record data on voltage, current, temperature, flow rate, pressure, and other process variables. Yokogawa is a leading manufacturer of recorders, and also holds a solid track record in the consulting industry with the use of machine learning to predict and analyze both equipment anomalies and product quality for manufacturers. To improve productivity and product quality, Yokogawa is now building user-friendly AI-related functions into its recorders, data logging software, and controllers. For example, these functions now enable GX/GP series recorders to draw waveforms on screen that are predicted based on the real-time analysis of collected data so that users can anticipate and correct problems early on, before they have a chance to escalate. Also, the e-RT3 Plus edge computing platform has been enhanced with the addition of support for Python, a programming language that is widely used in AI R&D.
Enhancements
-
AI future pen function for drawing of predicted waveforms
A future pen function has been added to the GX/GP series recorders to enable the drawing of predicted waveforms based on the use of AI to analyze collected data in real time. By viewing predicted waveforms up to a specified time point, users can identify the likelihood that an alarm will occur and take action in advance. An industry first, this adds an entirely new dimension to the capabilities of recorders, whose collection and recording of data has conventionally been used to visualize the past and present performance of various types of equipment.
-
Detection of anomalies and prediction of potential failures
A machine learning function has been added to the GA10 data logging software that can acquire normal process values from correctly operating devices and use these values to detect an anomaly and predict a potential failure, a capability that up till now has only been possessed by the most expert operators. Data on which device is expected to fail is displayed on screen, highlighted within a yellow frame. Maintenance can thus be performed before the device fails, minimizing the likelihood of any disruptions to production. This function does not necessitate the collection of abnormal process values and thus is easy to implement.
-
Addition of Python support
e-RT3 Plus controllers can be built into various types of devices. For use with these controllers, Yokogawa is releasing a new CPU module that supports Python, a programming language that is widely used in machine learning and other branches of the AI field. The large library of software written in this language includes numerous tools that programmers can use to speed up their development of AI predictive diagnostic functions. This new CPU module also has excellent environmental resistance, and easily accommodates existing input/output (IO) modules. The addition of this new module to the e-RT3 Plus edge computing platform will enable the introduction of AI solutions in a wider range of industries.
For added flexibility, the new e-RT3 Plus controllers run on Linux Ubuntu*3 , a general-purpose operating system.
Major Target Markets
GX series: Production sites in a wide range of industries including iron and steel, electric power, chemicals, pulp and paper, foods, pharmaceuticals, heat treatment equipment, water supply and wastewater treatment, electrical equipment, and electronics
GP series: Companies engaged in R&D of home appliances, automobiles, semiconductors, and new-energy related technologies as well as academic institutions and research institutes
GA10: Both of the above
e-RT3 Plus: Manufacturers of industrial machinery and companies engaged in the assembly of electronic components and devices
Applications
Monitoring and recording of voltage, current, temperature, flow rate, pressure, and other process variables; evaluation of performance in equipment management, production, and product development; safety and reliability evaluation during product quality inspection processes
*1 A versatile programming language that is widely used in AI application development. Designed to be user-friendly with simple code, Python enables users to write various programs in a clear manner with fewer lines of code than other languages. In addition, numerous Python open-source libraries are available for use in machine learning and other AI applications.
*2 Based on a March 2020 Yokogawa survey
*3 A Linux distribution and installation package provided by Canonical Ltd., a UK-based software company
About SMARTDAC+
SMARTDAC+ stands for smart data acquisition and control, and the SMARTDAC+ system includes a variety of IO modules and options. With the product lineup of the GX series panel-mount type paperless recorders, GP series portable paperless recorders, GA10 data logging software, and GM series data acquisition systems, SMARTDAC+ offers extensive support for manufacturing process monitoring and performance evaluation.
For more information
https://www.yokogawa.com/ai-products/
About OpreX
OpreX is the comprehensive brand for Yokogawa's industrial automation (IA) and control business. The OpreX name stands for excellence in the technologies and solutions that Yokogawa cultivates through the co-creation of value with its customers, and encompasses the entire range of Yokogawa's IA products, services, and solutions. This brand comprises the following five categories: OpreX Transformation, OpreX Control, OpreX Measurement, OpreX Execution, and OpreX Lifecycle. The SMARTDAC+ data acquisition and control system is part of the OpreX Data Acquisition lineup, which is aligned under the OpreX Measurement category. The OpreX Measurement category includes field equipment and systems for highly precise measurement, data collection, and analysis.
With this brand, Yokogawa will deliver integrated solutions that address specific needs and support its customers in their efforts to transform and grow their businesses.
About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com
.
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005269/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom